What the FDA labels say about taking them together
Cobicistat, darunavir, emtricitabine and tenofovir alafenamide and fluvastatin
Cobicistat, darunavir, emtricitabine and tenofovir alafenamide's FDA label of April 17, 2026 names fluvastatin in its drug interactions section; the fluvastatin labels PlainMeds reads (2) do not name cobicistat, darunavir, emtricitabine and tenofovir alafenamide. The cobicistat, darunavir, emtricitabine and tenofovir alafenamide label: “For atorvastatin, fluvastatin, pitavastatin, pravastatin, and rosuvastatin, start with the lowest recommended dose and titrate while monitoring for safety.”
Check it at the source: the cobicistat, darunavir, emtricitabine and tenofovir alafenamide FDA label on DailyMed (effective April 17, 2026, Janssen Products LP); the fluvastatin FDA label on DailyMed (effective April 21, 2025, Teva Pharmaceuticals USA, Inc.).
What does the cobicistat, darunavir, emtricitabine and tenofovir alafenamide label say about fluvastatin?
Cobicistat, darunavir, emtricitabine and tenofovir alafenamide label, drug interactionsConcomitant Drug Class/Drug Name Examples: e.g., atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin; Effect on Concentration: ↑ atorvastatin ↑ fluvastatin ↑ pravastatin ↑ rosuvastatin pitavastatin: effect unknown; Clinical Comment: For atorvastatin, fluvastatin, pitavastatin, pravastatin, and rosuvastatin, start with the lowest recommended dose and titrate while monitoring for safety.
Source: FDA drug label (Symtuza), Janssen Products LP, effective April 17, 2026 (SPL set 85a17d00-6b7c-41ea-a6b3-5ad924820dab), via openFDA; the full label on DailyMed
What does the fluvastatin label say about cobicistat, darunavir, emtricitabine and tenofovir alafenamide?
Fluvastatin's label (effective April 21, 2025) and its 1 other brand-application label do not name cobicistat, darunavir, emtricitabine and tenofovir alafenamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Fluvastatin), Teva Pharmaceuticals USA, Inc., effective April 21, 2025 (SPL set aad8b373-0aec-4efb-8e61-3d8114b31127), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat, darunavir, emtricitabine and tenofovir alafenamide | Fluvastatin | |
|---|---|---|
| Labeled for | HIV | High cholesterol |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $152.87 per tablet 800-150-200-10 mg tablet | $2.88 per tablet 80 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once